Commentary

Article

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD

Speakers

  • Jeremy Allred, MD | Masonic Cancer Center
  • Joseph Maakaron, MD | Masonic Cancer Center
  • Marie Hu, MD | Masonic Cancer Center
  • Craig Eckfeldt, MD, PhD | Masonic Cancer Center
  • Daniel O'Leary, MD | Masonic Cancer Center
  • Mark Juckett, MD, MHCM | Masonic Cancer Center
  • Sanjal Desai, MD | Masonic Cancer Center

Topics

  • Current and Emerging Treatment Standards for Myelodysplastic Syndrome
  • Debate! Bispecific Antibodies vs CAR T in R/R DLBCL
  • Treatment Crossroads: How do you sequence bispecifics and CAR T in Myeloma?
  • Emerging Agents in R/R AML
  • Sequencing Therapies in CLL

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study